Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of TQB3909 in relapsed or refractory CLL/SLL
CTR20232112Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3909 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Nanjing Shunxin Pharmaceutical. Started Oct 2023; status: active.
02
Drugs
TQB3909
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20232112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232112.